Supreme Court Slams Massive Markups on Essential Medicines, Reserves Order on Trade Margin Regulations

The Supreme Court of India sharply criticized the regulatory oversight of pharmaceutical pricing in the country, questioning why the existing mechanism permits an immense disparity between the procurement cost of medicines and their maximum retail price (MRP). A Bench comprising Justice Vikram Nath and Justice Sandeep Mehta raised grave concerns while hearing petitions addressing excessive markups by pharmaceutical manufacturers and private hospitals.

The Bench observed that the National Pharmaceutical Pricing Authority (NPPA) appeared "totally defunct" in curbing unconscionable profit margins that leave vulnerable patients burdened by inflated healthcare costs. The court cited stark real-world disparities, including instances where life-saving injections purchasable in the wholesale trade for approximately ₹11,000 were billed to patients at upwards of ₹1.3 lakh. Following extensive arguments from the petitioners and the Union Government, the Supreme Court reserved its order in the matter.

Legal Topic

Area of Law: Healthcare & Regulatory Law

Sub-topic: Drug Price Regulation / Consumer Protection & Public Health

Core Legal Issue

The core legal question centers on the scope and effectiveness of statutory price control mechanisms governing pharmaceuticals under Indian law. Specifically, the court is examining whether the Central Government and the NPPA are failing in their statutory obligations by allowing pharmaceutical companies and distributor networks to inflate MRPs through unrestrained trade margins on non-scheduled and critical life-saving medications.

The broader constitutional dimension touches on whether the failure to regulate arbitrary profit markups on essential healthcare products violates the fundamental right to health and affordable medical treatment implicit in Article 21 of the Constitution of India.

What Did the Court Decide?

The Supreme Court did not issue a final judgment but concluded oral hearings and reserved its formal order. During the proceedings, the Bench made several critical observations and signaled potential judicial directives:

• Scrutiny of Regulatory Inaction: The court questioned the efficacy of the NPPA, noting that the agency seems inactive while pharmaceutical entities extract high markups under the administration's watch.

• Inadequacy of Limited Relief: The Bench noted that the government’s move to cap trade margins at 30% solely for anti-cancer drugs was insufficient, questioning why similar trade margin caps are not routinely extended across other vital therapeutic categories.

• Interim Status: The bench heard comprehensive submissions from the Central Government and stakeholders before reserving orders to determine whether specific binding guidelines or policy directions should be issued to the Centre.

Key Legal Points

• Regulatory Oversight Deficits: The Bench highlighted that leaving wide gaps between manufacturer prices, retailer acquisition costs, and final consumer MRP amounts to an unmonitored commercial practice that the executive has permitted without adequate statutory intervention.

• Expansion of Trade Margin Rationalization: The proceedings spotlight the legal necessity of widening margin caps beyond oncology treatments to cover a broader basket of essential drugs.

• Vulnerability of Healthcare Consumers: The court reiterated that patients facing severe illnesses possess no bargaining power, making commercial pricing exploitation in critical healthcare a direct concern for public interest jurisdiction.

• Public Function of Drug Regulators: The statutory mandate of the NPPA under the Drugs (Prices Control) Order cannot be treated as discretionary when life-saving affordability is undermined.

Relevant Law

• Drugs (Prices Control) Order, 2013 (DPCO): Issued under the Essential Commodities Act to regulate ceiling prices of scheduled formulations and monitor the retail prices of non-scheduled formulations.

• Section 3 of the Essential Commodities Act, 1955: Empowers the Central Government to control the production, supply, and distribution of essential commodities, including drugs, at fair prices.

• National Pharmaceutical Pricing Authority Mandates: Government notifications establishing the enforcement powers and monitoring functions of the drug pricing regulator.

• Article 21 of the Constitution of India: The fundamental right to life, which the Supreme Court has consistently held encompasses access to healthcare and affordable life-saving medicines.

Arguments of the Parties

Petitioners / Public Interest Litigants The petitioners submitted that the prevailing pricing regime enables pharmaceutical companies to establish artificial, inflated MRPs. This structure permits private hospitals and distributors to pocket exorbitant margins at the expense of patients who are compelled to buy prescribed medicines at the printed retail price. They argued that the government must cap trade margins across all vital medical formulations, rather than limiting intervention to a small fraction of specialized drugs.

Respondent / Union of India Appearing for the Centre, Additional Solicitor General Aishwarya Bhati argued that drug prices in India remain among the most affordable in the world. The government submitted that it has undertaken substantial regulatory measures, including capping trade margins on anti-cancer drugs at 30% of the MRP, an intervention estimated to yield annual patient savings of roughly ₹2,500 crore. The Centre contended that balancing affordability with the commercial viability and research investments of the pharmaceutical industry requires careful policy coordination.

Why Does It Matter?

This development signals a significant judicial push toward tightening the loose pricing corridors that currently exist for non-scheduled drugs and hospital supplies. While scheduled medicines listed in the National List of Essential Medicines (NLEM) are governed by strict ceiling prices under the DPCO, non-scheduled medicines are largely subject only to annual price hike ceilings of 10%. This regulatory loophole has allowed manufacturers and hospitals to set arbitrarily high base MRPs.

If the Supreme Court’s reserved directions mandate an across-the-board trade margin rationalization framework, private hospitals and pharmaceutical distributors will face mandatory caps on markup structures. For consumers and patients, such an intervention could substantially lower out-of-pocket medical expenditures, addressing one of the most prominent financial vulnerabilities for families undergoing critical medical care.

Legal Takeaway

The Supreme Court's scrutiny emphasizes that drug price regulation is not merely an economic policy matter, but a critical component of the constitutional right to health. Regulators cannot permit excessive margins between retailer procurement costs and consumer MRPs under the guise of free-market flexibility when patient vulnerability eliminates ordinary consumer choice.

Sources

Primary Source:

• Proceedings before the Supreme Court of India, Bench of Justices Vikram Nath and Sandeep Mehta (Submissions heard and order reserved on October 27, 2026).

Additional Sources:

• Drugs (Prices Control) Order, 2013, Ministry of Chemicals and Fertilizers, Government of India.

• National Pharmaceutical Pricing Authority (NPPA) notifications on Trade Margin Rationalization (TMR).